Payment overview · 2025
General Payments
$1,295.39
51 reported records · 16 companies
Healthcare provider profile · identity verified
David D Suh, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · TUCKER, GA · NPI 1366436297
Verified facts
What the public records show
CMS Open Payments records show David D Suh, MD received $1,295.39 in general payments during 2025 across 51 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 597 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 597 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYNDAMAX as an associated drug or biological on 1880 records involving 1527 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Vyndamax by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $247.87 | 19.1% | 10 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $185.48 | 14.3% | 4 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $151.94 | 11.7% | 6 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $119.83 | 9.2% | 5 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $109.73 | 8.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $105.80 | 8.2% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $102.79 | 7.9% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $65.83 | 5.1% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $60.80 | 4.7% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.75 | 2.8% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $26.26 | 2.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.16 | 1.6% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $20.05 | 1.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.12 | 1.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.20 | 1.2% | 1 | 2025 |
| VivaQuant Inc, dba Rhythm Express | Unresolved — no canonical attribution shown | $5.78 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,295.39 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $161.84 | 3 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $151.94 | 6 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $148.62 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $119.83 | 5 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $109.73 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $100.41 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $87.69 | 3 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $86.06 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $65.83 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $60.80 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $53.02 | 3 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $36.75 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $26.34 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $26.26 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.76 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.76 | 1 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| TRYVIO Normalized: tryvio |
Drug | IDORSIA PHARMACEUTICALS US INC | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.12 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| RHYTHM EXPRESS Normalized: rhythm express |
Device | VivaQuant Inc, dba Rhythm Express | $5.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 597 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 85 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 83 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 94 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
85 | 22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 23 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
597 | 167 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
91 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
94 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
597 | 167 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | VYNDAMAX open payments reported associated product |
CMS Open Payments — General Payments 1880 supporting records · 1527 recipient NPIs · example record 1228795749 |
Vyndamax · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1251 | 402 |
| Metoprolol Succinate | Metoprolol Succinate | 934 | 303 |
| Carvedilol | Carvedilol | 917 | 284 |
| Losartan Potassium | Losartan Potassium | 719 | 218 |
| Amlodipine Besylate | Amlodipine Besylate | 648 | 205 |
| Eliquis | Apixaban | 597 | 167 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 593 | 201 |
| Spironolactone | Spironolactone | 423 | 145 |
| Clopidogrel | Clopidogrel Bisulfate | 380 | 119 |
| Lisinopril | Lisinopril | 304 | 96 |
| Hydrochlorothiazide | Hydrochlorothiazide | 225 | 73 |
| Furosemide | Furosemide | 222 | 93 |
| Xarelto | Rivaroxaban | 198 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 64 |
| Sotalol | Sotalol Hcl | 174 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 164 | 56 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 155 | 43 |
| Celecoxib | Celecoxib | 141 | 59 |
| Famotidine | Famotidine | 137 | 54 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 123 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 122 | 39 |
| Metformin Hcl | Metformin Hcl | 119 | 40 |
| Omeprazole | Omeprazole | 103 | 40 |
| Gabapentin | Gabapentin | 97 | 31 |
| Valsartan | Valsartan | 96 | 30 |
| Ozempic | Semaglutide | 94 | 28 |
| Entresto | Sacubitril/Valsartan | 91 | 26 |
| Potassium Chloride | Potassium Chloride | 87 | 29 |
| Amiodarone Hcl | Amiodarone Hcl | 85 | 30 |
| Farxiga | Dapagliflozin Propanediol | 85 | 22 |
| Methylprednisolone | Methylprednisolone | 84 | 56 |
| Nebivolol Hcl | Nebivolol Hcl | 84 | 33 |
| Jardiance | Empagliflozin | 83 | 23 |
| Repatha Sureclick | Evolocumab | 80 | 17 |
| Torsemide | Torsemide | 71 | 26 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 67 | 25 |
| Telmisartan | Telmisartan | 67 | 21 |
| Ezetimibe | Ezetimibe | 64 | 23 |
| Allopurinol | Allopurinol | 61 | 20 |
| Mounjaro | Tirzepatide | 60 | 16 |
| Trazodone Hcl | Trazodone Hcl | 60 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 21 |
| Warfarin Sodium | Warfarin Sodium | 55 | 12 |
| Glimepiride | Glimepiride | 53 | 20 |
| Nifedipine Er | Nifedipine | 52 | 18 |
| Nitroglycerin | Nitroglycerin | 52 | 26 |
| Terazosin Hcl | Terazosin Hcl | 52 | 11 |
| Eplerenone | Eplerenone | 48 | 14 |
| Sertraline Hcl | Sertraline Hcl | 47 | 18 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 46 | 16 |
| Atenolol | Atenolol | 45 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 45 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 13 |
| Trulicity | Dulaglutide | 41 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 40 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | 13 |
| Flecainide Acetate | Flecainide Acetate | 39 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 35 | 16 |
| Labetalol Hcl | Labetalol Hcl | 33 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Simvastatin | Simvastatin | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | 11 |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Colchicine | Colchicine | 24 | 11 |
| Prasugrel Hcl | Prasugrel Hcl | 23 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 18 |
| Vyndamax | Tafamidis | 21 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 14 |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 17 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 13 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Edarbi | Azilsartan Medoxomil | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,295.39 · 51 records | AstraZeneca Pharmaceuticals LP | AMVUTTRA, Attruby, CAMZYOS, CAPVAXIVE, ELIQUIS, FARXIGA, INSPIRE, JARDIANCE, LEQVIO, LifeVest, MITRACLIP, OPSUMIT, OPSYNVI, Ozempic, REPATHA, RHYTHM EXPRESS, Rybelsus, TRYVIO, UPTRAVI, VERQUVO, VYNDAQEL, WAINUA, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error